Literature DB >> 31972648

Local Recurrence After Transanal Total Mesorectal Excision for Rectal Cancer: A Multicenter Cohort Study.

Sapho Xenia Roodbeen1, Antonino Spinelli2,3, Willem A Bemelman1, Francesca Di Candido2, Maylis Cardepont4, Quentin Denost4, Andre D'Hoore5, Bert Houben6, Joep J Knol6, Beatriz Martín-Pérez5, Eric Rullier4, Dana Sands7, Ilana Setton7, Katrien Van de Steen6, Pieter J Tanis1, Steven D Wexner7, Roel Hompes1, Albert M Wolthuis5.   

Abstract

OBJECTIVE: This study aimed to determine local recurrence (LR) rate and pattern after transanal total mesorectal excision (TaTME) for rectal cancer.
BACKGROUND: TaTME for mid- and low rectal cancer has known a rapid and worldwide adoption. Recently, concerns have been raised on the oncological safety in light of reported high LR rates with a multifocal pattern.
METHODS: This was a multicenter observational cohort study in 6 tertiary referral centers. All consecutive TaTME cases for primary rectal adenocarcinoma from the first TaTME case in every center until December 2018 were included for analysis. Patients with benign tumors, malignancies other than adenocarcinoma and recurrent rectal cancer, as well as exenterative procedures, were excluded. The primary endpoint was 2-year LR rate. Secondary endpoints included patterns and treatment of LR and histopathological characteristics of the primary surgery.
RESULTS: A total of 767 patients were identified and eligible for analysis. Resection margins were involved in 8% and optimal pathological outcome (clear margins, (nearly) complete specimen, no perforation) was achieved in 86% of patients. After a median follow-up of 25.5 months, 24 patients developed LR, with an actuarial cumulative 2-year LR rate of 3% (95% CI 2-5). In none of the patients, a multifocal pattern of LR was observed. Thirteen patients had isolated LR (without systemic disease) and 10/13 could be managed by salvage surgery of whom 8 were disease-free at the end of follow-up. CONCLUSIONS AND RELEVANCE: This study shows good loco regional control after TaTME in selected cases from tertiary referral centers and does not indicate an inherent oncological risk of the surgical technique.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 31972648     DOI: 10.1097/SLA.0000000000003757

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  17 in total

Review 1.  Limitations and Concerns with Transanal Total Mesorectal Excision for Rectal Cancer.

Authors:  M Vannijvel; Albert M Wolthuis
Journal:  Clin Colon Rectal Surg       Date:  2022-02-28

Review 2.  Mesentery in Transanal TME.

Authors:  Joep Knol; Sami A Chadi
Journal:  Clin Colon Rectal Surg       Date:  2022-08-10

Review 3.  Locally Recurrent Rectal Cancer According to a Standardized MRI Classification System: A Systematic Review of the Literature.

Authors:  Zena Rokan; Constantinos Simillis; Christos Kontovounisios; Brendan Moran; Paris Tekkis; Gina Brown
Journal:  J Clin Med       Date:  2022-06-18       Impact factor: 4.964

4.  Systematic review of classification systems for locally recurrent rectal cancer.

Authors:  Z Rokan; C Simillis; C Kontovounisios; B J Moran; P Tekkis; G Brown
Journal:  BJS Open       Date:  2021-05-07

Review 5.  Introduction of new techniques and technologies in surgery: Where is transanal total mesorectal excision today?

Authors:  Antonio Caycedo-Marulanda; Sunil Patel; Shaila Merchant; Carl Brown
Journal:  World J Gastrointest Surg       Date:  2020-05-27

6.  Association of Transanal Total Mesorectal Excision With Local Recurrence of Rectal Cancer.

Authors:  Antonio Caycedo-Marulanda; Lawrence Lee; Sami A Chadi; Chris P Verschoor; Jordan Crosina; Shady Ashamalla; Carl J Brown
Journal:  JAMA Netw Open       Date:  2021-02-01

7.  Role of Preoperative Chemoradiotherapy in Clinical Stage II/III Rectal Cancer Patients Undergoing Total Mesorectal Excision: A Retrospective Propensity Score Analysis.

Authors:  Jii Bum Lee; Han Sang Kim; Ahrong Ham; Jee Suk Chang; Sang Jun Shin; Seung-Hoon Beom; Woong Sub Koom; Taeil Kim; Yoon Dae Han; Dai Hoon Han; Hyuk Hur; Byung Soh Min; Kang Young Lee; Nam Kyu Kim; Yu Rang Park; Joon Seok Lim; Joong Bae Ahn
Journal:  Front Oncol       Date:  2021-01-18       Impact factor: 6.244

8.  Transanal versus conventional total mesorectal excision for rectal cancer using the IDEAL framework for implementation.

Authors:  R L Robertson; A Karimuddin; T Phang; M Raval; C Brown
Journal:  BJS Open       Date:  2021-03-05

9.  Cutaneous Stomal Recurrence of Colorectal Cancer After Curative Rectal Cancer Surgery - A Case Report and Systematic Review.

Authors:  Simon Davey; Kathryn McCarthy
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

Review 10.  Clinical Status and Future Prospects of Transanal Total Mesorectal Excision.

Authors:  Zichao Guo; Xiaopin Ji; Shaodong Wang; Yaqi Zhang; Kun Liu; Changgang Wang; Yang Deng; Tao Zhang; Xi Cheng; Ren Zhao
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.